Cadrenal Therapeutics elects Steven Zelenkofske as director; ratifies auditor

Cadrenal Therapeutics, Inc.

At 2025 annual meeting, stockholders elected Steven Zelenkofske as Class III director with 669,494 votes for, 15,099 withheld.
Ratification of WithumSmith+Brown as FY2025 auditor passed with 1,207,152 votes for, 64,913 against, 12,681 abstain.
Broker non-votes of 600,153 on director election; none on auditor ratification (routine matter).
Meeting held September 24, 2025; quorum of 1,284,746 shares out of 2,046,854 outstanding.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.